Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 3
2009 3
2010 3
2011 3
2012 8
2013 14
2014 21
2015 13
2016 22
2017 23
2018 21
2019 17
2020 25
2021 19
2022 16
2023 23
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
An 18F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy.
Thor M, Lee C, Sun L, Patel P, Apte A, Grkovski M, Shepherd AF, Gelblum DY, Wu AJ, Simone CB 2nd, Chaft JE, Rimner A, Gomez DR, Deasy JO, Shaverdian N. Thor M, et al. Among authors: gomez dr. J Nucl Med. 2024 Apr 1;65(4):520-526. doi: 10.2967/jnumed.123.266965. J Nucl Med. 2024. PMID: 38485270
Response letter to "Stereotactic body radiation therapy for pleural mesothelioma: Which goal, which patients".
Shin JY, Offin M, Simone CB 2nd, Shepherd AF, Wu AJ, Shaverdian N, Gelblum DY, Gomez DR, Sauter JL, Ginsberg MS, Adusumilli PS, Rusch VW, Zauderer MG, Rimner A. Shin JY, et al. Among authors: gomez dr. Radiother Oncol. 2024 Apr;193:110138. doi: 10.1016/j.radonc.2024.110138. Epub 2024 Feb 10. Radiother Oncol. 2024. PMID: 38342346 No abstract available.
Clinical and Dosimetric Risk Factors Associated With Radiation-Induced Lung Toxicities After Multiple Courses of Lung Stereotactic Body Radiation Therapy.
Li X, Yorke E, Jackson A, Yue Y, Simone CB 2nd, Apte AP, Rimner A, Gomez DR, Shaverdian N, Gelblum DY, Wu AJ, Shepherd AF. Li X, et al. Among authors: gomez dr. Adv Radiat Oncol. 2023 Jun 7;9(1):101284. doi: 10.1016/j.adro.2023.101284. eCollection 2024 Jan. Adv Radiat Oncol. 2023. PMID: 38260213 Free PMC article.
Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial.
Rimner A, Gelblum DY, Wu AJ, Shepherd AF, Mueller B, Zhang S, Cuaron J, Shaverdian N, Flynn J, Fiasconaro M, Zhang Z, von Reibnitz D, Li H, McKnight D, McCune M, Gelb E, Gomez DR, Simone CB 2nd, Deasy JO, Yorke ED, Ng KK, Chaft JE. Rimner A, et al. Among authors: gomez dr. Int J Radiat Oncol Biol Phys. 2023 Dec 26:S0360-3016(23)08252-4. doi: 10.1016/j.ijrobp.2023.12.018. Online ahead of print. Int J Radiat Oncol Biol Phys. 2023. PMID: 38154510
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma.
Shin JY, Offin M, Simone CB 2nd, Zhang Z, Shepherd AF, Wu AJ, Shaverdian N, Gelblum DY, Gomez DR, Sauter JL, Ginsberg MS, Adusumilli PS, Rusch VW, Zauderer MG, Rimner A. Shin JY, et al. Among authors: gomez dr. Radiother Oncol. 2024 Feb;191:110057. doi: 10.1016/j.radonc.2023.110057. Epub 2023 Dec 15. Radiother Oncol. 2024. PMID: 38104783
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group. Tsai CJ, et al. Among authors: gomez dr. Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104577 Clinical Trial.
Safety and efficacy of stereotactic body proton therapy for high-risk lung tumors.
McMillan MT, Shepherd AF, Kang M, Lin L, Shaverdian N, Wu AJ, Gelblum DY, Ohri N, Lazarev S, Xu L, Chhabra AM, Hasan S, Choi JI, Gomez DR, Rimner A, Lin H, Simone CB. McMillan MT, et al. Among authors: gomez dr. J Radiosurg SBRT. 2023;9(1):63-74. J Radiosurg SBRT. 2023. PMID: 38029007 Free PMC article.
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer.
Alessi JV, Price A, Richards AL, Ricciuti B, Wang X, Elkrief A, Pecci F, Di Federico A, Gandhi MM, Lebow ES, Santos PMG, Thor M, Rimner A, Schoenfeld AJ, Chaft JE, Johnson BE, Gomez DR, Awad MM, Shaverdian N. Alessi JV, et al. Among authors: gomez dr. J Immunother Cancer. 2023 Nov;11(11):e007618. doi: 10.1136/jitc-2023-007618. J Immunother Cancer. 2023. PMID: 37914383 Free PMC article.
204 results